Loading…
← CockpitCompetitor Analysis › OBIO Orchestra BioMed Holdings, Inc.Open in the cockpit ↗

Orchestra BioMed Holdings, Inc.OBIOCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 98
Mkt cap
$587M
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$3.64M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.6%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · USD$7.46
1D+7.0%
1W+24.1%
1M+28.2%
3M+37.4%
6M+87.4%
YTD+79.8%
1Y+80.6%
ATR %6.7%
Beta1.52
52w lowhigh4.7% off high

What Orchestra BioMed does

Employees: 86

Orchestra BioMed at a glance

Size Orchestra BioMed (OBIO) is a United States Health Care company (Medical Specialties) with a market value of $587M, the 2561st largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.46 on 18 Nov 2026.

Performance Over six months the shares gained 87.4%, against -12.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.

Growth Revenue grew 1,007.4% over the last twelve months (peer median +6.5%); the operating margin is -195.4% (peer median 7.5%).

Valuation It trades at 18.3× enterprise value to sales against a peer median of 5.4× (2nd most expensive of 20).

Backlog Backlog (remaining performance obligations) was $11.0M at 31 Dec 2025, up 150% on a year earlier — 0.3 years of trailing revenue. Backlog detail →

Short interest Short interest is 4.5% of the free float (30 Oct 2026).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026OBIO 182Peer median 89
Six months, rebased to 100: Orchestra BioMed against the median of its 20 peers (local-currency closes).

Orchestra BioMed financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$31.2M$33.5M$2.64M$2.76M$3.53M
Revenue growth—+1,169%-4%-22%—
Gross profit$30.8M$33.1M$2.28M$2.43M$3.21M
EBITDA-$60.6M-$51.5M-$64.0M-$51.2M-$32.4M
Net income-$57.0M-$52.7M-$61.0M-$49.1M-$33.6M
Free cash flow-$64.2M-$49.5M-$50.8M-$46.2M-$29.9M
Capital expenditure$869,000$489,000$289,000$78,000$591,000
Total debt$73.5M$32.4M$16.5M$1.69M$11.9M

Quarterly statements and history in the cockpit →

Orchestra BioMed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+50%300314688581TCMDSGHTMEDINAN300952PACBXVIVO3012356031226882364728300869ZJYLMYGNOBIO6-month return →1-month return →
Up and to the right = strong over both horizons. Orchestra BioMed is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%0×10×20×300314688581TCMDVVVVMEDI3012354728605369ZJYLOBIORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Orchestra BioMed is the large dot.

Orchestra BioMed competitors and peer comparison

How Orchestra BioMed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Orchestra BioMed against its 20 peers (data as of 18 Nov 2026)
MeasureOBIOPeer medianRank in peer set
1-month return+28.2%-1.9%2nd highest of 19
6-month return+87.4%-12.6%2nd highest of 19
Distance from 52-week high-4.7%-34.3%2nd highest of 20
Revenue growth (TTM)+1,007.4%+6.5%highest of 20
Operating margin-195.4%7.5%lowest of 20
EV / Sales18.3×5.4×2nd most expensive of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%18.3×n/an/a
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%5.4×n/an/a
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%3.7×0.4%+27.8%
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%1.5×8.4%+12.0%
vVARDIS VVVVUnited States$594Mn/a+148%-72%14.3×n/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
Sight Sciences SGHTUnited States$599M+122%+16%-30%6.4×n/an/a
Medistim MEDI.OLNorway$599M+32%+19%29%7.1×-1.2%+14.5%
Nanosonics NAN.AXAustralia$599M-4%+3%7%3.8×35.3%+6.7%
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%6.7×n/an/a
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%6.3×35.9%+35.2%
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%1.6×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%2.1×-8.5%+2.2%
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%8.3×-2.6%+18.8%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
AK Medical 1789.HKHong Kong$642M-23%+16%26%2.1×-11.5%+6.7%
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a

Orchestra BioMed backlog

Orchestra BioMed reported $11.0M of remaining performance obligations at 31 Dec 2025, up 150% from a year earlier. That is 0.3 years of trailing revenue already under contract.

Questions

Which companies are Orchestra BioMed's closest peers?
The cockpit's peer set: Ningbo David Medical Device (300314.SZ), Hangzhou AGS MedTech (688581.SS), Tactile Systems Technology (TCMD), vVARDIS (VVVV), Sahajanand Medical Technologies (SMT.NS), Sight Sciences (SGHT), Medistim (MEDI.OL), Nanosonics (NAN.AX).
Is Orchestra BioMed expensive compared with its peers?
On ev / sales it trades at 18.3× against a peer median of 5.4×, 2nd most expensive of 20 in its peer set.
How has Orchestra BioMed stock performed?
Over six months to 18 Nov 2026 the shares returned +87.4% against -12.6% for the median peer; over one year +80.6%.
What is Orchestra BioMed's backlog?
Orchestra BioMed's remaining performance obligations (contracted revenue not yet recognised) were $11.0M at 31 Dec 2025, +150% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.